ArticleLung2018
The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases.
Article in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Advances in management of sarcoidosis-associated fatigue: A narrative review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Impact of comorbidities and organ damage on hospital admissions and mortality in patients with sarcoidosis: an observational study from the Spanish National Registry.Internal and emergency medicine · 2026Observational
- Age, comorbidity, race and gender differences in referral to a pulmonologist among patients with sarcoidosis at a large academic medical center.BMC pulmonary medicine · 2025Article
- Article
- Clinical outcomes following hospitalization for COVID-19 in patients with cardiac sarcoidosis in the United States: a propensity-matched analysis from national inpatient sample database from April 2020 to December 2021.Annals of medicine and surgery (2012) · 2024Article
- Sarcoidosis and lymphoma mortality risk: An observational study from the Spanish National Registry.Journal of translational autoimmunity · 2024Article
- Is a Vitamin K Epoxide Reductase Complex Subunit 1 (International journal of molecular sciences · 2024Article
- Demographics, Cutaneous Manifestations, and Comorbidities Associated with Progressive Cutaneous Sarcoidosis: A Retrospective Cohort Study.Medicines (Basel, Switzerland) · 2023Article
- Article
- Safety of corticosteroid therapy in sarcoidosis treatment.Frontiers in drug safety and regulation · 2023Review
- Comorbidities of sarcoidosis.Annals of medicine · 2022Review
- Article
- Sarcoidosis in Johannesburg, South Africa: A retrospective study.African journal of thoracic and critical care medicine · 2022Article
- Elderly Onset Sarcoidosis: A Case Report.Cureus · 2021Article
- A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.Pulmonary therapy · 2021Review
- A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.Pulmonary therapy · 2021Review
- Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids.ERJ open research · 2021Article
- Comprehensive Care for Patients with Sarcoidosis.Journal of clinical medicine · 2020Review
- Sarcoidosis and increased risk of comorbidities and mortality in sweden.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Article
- The incidence, comorbidity and mortality of sarcoidosis in Korea, 2008-2015: a nationwide population-based study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate comorbidity, complexity and poor outcomes in patients with sarcoidosis and to compare those scores with a control group.
methods218 consecutive patients were diagnosed with sarcoidosis according to the ATS/ERS/WASOG criteria; extrathoracic involvement was evaluated using the 2014 WASOG organ assessment instrument. Sarcoidosis patients were compared with an age- and gender-matched control group of primary care outpatients without sarcoidosis. Comorbidities were assessed retrospectively using the Charlson Comorbidity Index (CCI); complexity was evaluated according to the classification into Clinical Risk Groups (CRG) and severity levels.
resultsThe cohort included 142 women and 76 men; the mean age was 47.1 years at diagnosis of sarcoidosis and 55.9 years at the last visit. Patients with a CCI > 1 had a higher frequency of calcium/vitamin D abnormalities (p < 0.001), kidney involvement (p = 0.005) and a higher mortality rate (p < 0.001) compared with patients with a CCI ≤ 1. Patients with a CRG ≥ 6 had a higher frequency of extrathoracic involvement (p = 0.039), calcium/vitamin D abnormalities (p = 0.019) and treatment with glucocorticoids (p = 0.032) compared with patients with a CRG < 6. 11% patients died after a mean follow-up of 102.3 months. Country of birth, kidney involvement and extrathoracic disease were significantly associated with death. Patients with sarcoidosis had a higher frequency of liver (p < 0.001), pulmonary (p = 0.002) and autoimmune disease (p = 0.011) and cancer (p = 0.007) compared with the control group.
conclusionWe found higher rates of comorbidity and complexity in patients with sarcoidosis compared with a control group. Liver, pulmonary, autoimmune and neoplastic diseases were the main comorbidities found in patients with sarcoidosis.
Indexed as
Identifiers
29230534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.